Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ursodeoxycholic acid crossover trial for LPAC after cholecystectomy
ACTRN12621000450819Phase 3Recruiting
- Sponsor
- Melbourne Health
- Start
- May 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ursodeoxycholic acid in low phospholipid associated cholelithiasis (LPAC) (2 arms), sponsored by Melbourne Health. Primary endpoint: Number of episodes of biliary pain at 24 months. Started May 2022; status: recruiting.
02
Drugs
ursodeoxycholic acid
03
Conditions
low phospholipid associated cholelithiasis (LPAC)
Beyond the preview
Go deeper on ACTRN12621000450819.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12621000450819.